An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer

Biomaterials

Volumn 33, Issue 15, 2012, Pages 3919-3930

  Yang, Hung Wei ^a   Hua, Mu Yi ^a   Liu, Hao Li ^a   Tsai, Rung Ywan ^b   Pang, See Tong ^a,c   Hsu, Po Hong ^a   Tang, Hsiang Jun ^a   Yen, Tzu Chen ^c   Chuang, Cheng Keng ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Chemotherapy; Magnetic targeting; MRI; Multidrug resistance

Indexed keywords

BLADDER CANCERS; CARDIOTOXICITY; CHEMOTHERAPEUTIC AGENTS; DRUG RESISTANCE; EPIRUBICIN; HUMAN BLADDER CANCER; MAGNETIC TARGETING; MULTIDRUG RESISTANCE; NANOCARRIERS; NUCLEAR EXPORT; P-GLYCOPROTEIN; TUMOR SITE;

CELL MEMBRANES; CHEMOTHERAPY; CYTOLOGY; MAGNETIC RESONANCE IMAGING; MEDICAL NANOTECHNOLOGY;

DISEASES;

EPIRUBICIN; GLYCOPROTEIN P; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER LOCALIZATION; CARDIOTOXICITY; CELL MEMBRANE DRUG RESISTANCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; NUCLEAR DRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR PORE; PRIORITY JOURNAL;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; CONTRAST MEDIA; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETICS; MICE; NANOSTRUCTURES; PHANTOMS, IMAGING; TISSUE DISTRIBUTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

MUS;

EID: 84862826802     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.02.020     Document Type: Article

References (44)

1. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011, 14:150-164.
2. Dietel M. What's new in cytostatic drug resistance and pathology. Pathol Res Pract 1991, 187:892-905.
3. Morrow C.S., Cowan K.H. Glutathione S-transferases and drug resistance. Cancer Cells 1990, 2:15-22.
4. Hammond J.R., Johnstone R.M., Gros P. Enhanced efflux of (3H) vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr 1 gene. Cancer Res 1989, 49:3867-3871.
5. Beck W.T. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 1990, 17(Suppl. A):11-20.
6. Liu Y., Han T., Giuliano A.E., Cabot M.C. Ceramide glycosilation potentiates cellular multidrug resistance. FASEB J 2001, 15:719-730.
7. Desoize B., Jardillier J.C. Multicellular resistance: a paradigm for clinical resistance?. Crit Rev Oncol Hemat 2000, 36:193-207.
8. Vinagradov S.V., Bronich T.K., Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev 2002, 54:135-147.
9. Lewin J.M., Lwaleed B.A., Cooper A.J., Birch B.R. The direct effect of nuclear pores on nuclear chemotherapeutic concentration in multidrug resistant bladder cancer: the nuclear sparing phenomenon. J Urol 2007, 177:1526-1530.
10. Ribbeck K., Gorlich D. Kinetic analysis of translocation through nuclear pore complexes. EMBO J 2001, 20:1320-1330.
11. Bustamante J.O., Liepins A., Hanover J.A. Nuclear pore complex ion channels. Mol Mem Biol 1994, 11:141-150.
12. Zhang H., Gao F., Liu L., Li X., Zhou Z., Yang X., et al. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy. Colloid Surf B Biointerfaces 2009, 71:19-26.
13. Chang L.C., Wu S.C., Tsai J.W., Yu T.J., Tsai T.R. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery. Int J Pharm 2009, 376:195-203.
14. Wang Y.S., Liu L.R., Jiang Q., Zhang Q.Q. Self-aggregated nanoparticles of cholesterol-modified chitosan conjugate as a novel carrier of epirubicin. Eur Polym J 2007, 43:43-51.
15. Conroy S., Lee Jerry S.H., Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008, 60:1252-1265.
16. Azarmi S., Roa W.H., Löbenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008, 60:863. (8)-75.
17. Liu Z., Jiao Y., Wang Y., Zhou C., Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008, 60:1650-1662.
18. Kwon G.S., Okano T. Polymeric micelles as new drug carriers. Adv Drug Deliv Rev 1996, 21:107-116.
19. Kim J.O., Kabanov A.V., Bronich T.K. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Contr Release 2009, 138:197-204.
20. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
21. Liu H.L., Hua M.Y., Yang H.W., Huangd C.Y., Chua P.C., Wua J.S., et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci USA 2010, 107:15205-15210.
22. Hua M.Y., Yang H.W., Chuang C.K., Tsai R.Y., Chen W.J., Chuang K.L., et al. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 2010, 31:7355-7363.
23. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianna L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56:185-229.
24. Lo Y.I. Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol 2000, 60:1381-1390.
25. Geroni C., Ripamonti M., Arrigoni C., Fiorentini F., Capolongo L., Moneta D., et al. Pharmacological and toxicological aspects of 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent. Cancer Res 2001, 61:1983-1990.
26. Marchini S., Damia G., Broggini M., Pennella G., Ripamonti M., Marsiglio A., et al. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res 2001, 61:1991-1995.
27. Karmali P.P., Kotamraju V.R., Kastantin M., Black M., Missirlis D., Tirrell M., et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009, 5:73-82.
28. 2 nanoparticles with surfactants. Colloids Surf A Physicochem Eng Asp 2009, 348:270-275.
29. Nam H.Y., Kwon S.M., Chung H., Lee S.Y., Kwon S.H., Jeon H., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 2009, 135:259-267.
30. Ueda-Kawamitsu H., Lawson T.A., Gwilt P.R. In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 2002, 63:1209-1218.
31. Featherstone J.M., Lwaleed B.A., Speers A.G., Hayes M.C., Birch B.R., Cooper A.J. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines. Urology 2009, 74:378-384.
32. Gaston K.E., Pruthi R.S. Value of urinary cytology in the diagnosis and management of urinary tract malignancies. Urology 2004, 63:1009-1016.
33. Hendricksen K., Witjes W.P.J., Idema J.G., Kums J.J.M., van Vierssen Trip O.B., de Bruin M.J.F.M., et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol 2008, 53:984-991.
34. Dames P., Gleich B., Flemmer A., Hajek K., Seidl N., Wiekhorst F., et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol 2007, 2:495-499.
35. Dini L., Abbro L. Bioeffects of moderate-intensity static magnetic fields on cell cultures. Micron 2005, 36:195-217.
36. Danesi R., Fogli S., Gennari A., Conte P., Del Tacca M. Pharmacokinetic pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002, 41:431-444.
37. Hong J., Xu D., Gong P., Yu J., Ma H., Yao S. Covalent-bonded immobilization of enzyme on hydrophilic polymer covering magnetic nanogels. Microporous Mesoporous Mater 2008, 109:470-477.
38. Lee D.G., Ponvel K.M., Kim M., Hwang S., Ahn I.S., Lee C.H. Immobilization of lipase on hydrophobic nano-sized magnetite particles. J Mol Catal B Enzym 2009, 57:62-66.
39. Hua M.Y., Liu H.L., Yang H.W., Chen P.Y., Tsai R.Y., Huang C.Y., et al. The effectiveness of a magnetic-nanoparticle-based delivery system for BCNU in the treatment of Gliomas. Biomaterials 2011, 32:516-527.
40. Wang H., Ng T.B., Ooi V.E., Liu W.K. Effects of lectins with different carbohydrate binding specificities on hepatoma, choriocarcinoma, melanoma and osteosarcoma cell lines. Int J Biochem Cell Biol 2000, 32:365-372.
41. Kiyomiya K., Matsuo S., Kurebe M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 2001, 61:2467-2471.
42. Ström A.C., Weis K. Importin-β-like nuclear transport receptors. Genome Biol 2001, 2:3008.1-3008.9.
43. Pardridge W.M. Drug and gene delivery to the brain: the vascular route. Neuron 2002, 36:555-558.
44. Muldoon L.L., Soussain C., Jahnke K., Johanson C., Siegal T., Smith Q.R., et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25:2295-2305.